PMCB

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Wall Street analysts forecast PMCB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMCB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PharmaCyte Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

PharmaCyte Biotech Inc. EPS for the last quarter amounts to -1.23 USD, decreased -164.74 % YoY.

PharmaCyte Biotech Inc (PMCB) has 2 emplpoyees as of December 16 2025.

Today PMCB has the market capitalization of 6.40M USD.